Combinational BET and mTOR inhibition unveils EGR1 as acute myeloid leukemia prognostic biomarker

Abstract This study investigated the anti-leukemic potential of BET inhibitors in combination with mTOR inhibitors, focusing on both BET-resistant and BET-sensitive AML cell lines. Our findings reveal a significant suppression of proliferation and induction of apoptosis across all tested cell lines...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Marcela Teatin Latancia, Wellington Fernandes da Silva, Elayne Bragança-Jardim, Fernanda Fernandes Terra, Paula Fontes Asprino, Welbert De Oliveira Pereira, Vanessa Candiotti Buzatto, Pedro Alexandre Galante, Lilian Tiemi Inoue, Ana Rita Fonseca, Thais Nascimento Kimmemgs, Celso Arrais-Rodrigues, Vanderson Rocha, Yana Novis, Niels Olsen Saraiva Camara, Ana Paula Lepique, Luiz Fernando Lima Reis, Mariane Tami Amano
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-11-01
Edice:	Scientific Reports
Témata:	Leukemia mTOR Bromodomain Epigenetics Cancer treatment Inhibitors
On-line přístup:	https://doi.org/10.1038/s41598-025-24366-0
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!